News Hub | News Direct

What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Sunshine Biopharma Inc.

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. Apart from name difference, generic drugs work the same as an already marketed brand-name drug in dosage form, safety, strength, administration, quality, performance characteristics and intended use. Generic drug manufacturers can apply to the U.S. Food and Drug Administration (FDA) for permission to produce drugs when a patent expires. Generic drugs typically cost 80% to 85% less than branded drugs. If you look at your medications, chances are you will find one or more generic drugs such as ibuprofen, famotidine, metformin, metoprolol and amphetamine salt combo. Growing Global Generic Drugs Market The popularity, need for and use of these drugs are fueling the growth of the global generic drug market, which is expected to grow at a compound annual growth rate (CAGR) of 7.24% from 2022 to 2027. The market is expected to be worth $311.8 billion this year and $442.3 billion by 2027. Companies like Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Viatris Inc. (NASDAQ: VTRS) and Sunshine Biopharma Inc. (NASDAQ: SBFM) are researching, running trials and releasing products to meet demand. Strategic Acquisition By Sunshine Biopharma As the market continues to grow, strategic acquisitions like Sunshine Biopharma ’s recent purchase of Nora Pharma Inc. could help shape the future of the generic drugs market. Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares. The purchase price of approximately $21.9 million was paid by cash, Sunshine Biopharma common stock, and an earn-out amount. Nora Pharma is one of North America’s fastest-growing generic pharmaceutical companies, according to the news release issued Oct. 20. This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars. “The strategic acquisition of Nora Pharma significantly expands our revenue stream and is expected to generate multiyear top-line and bottom-line growth going forward,” Sunshine Biopharma CEO Steve Slilaty said. “This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.” Nora Pharma Founder and President said Sunshine will provide additional expertise that will help Nora with its accelerated growth plan to provide high-quality, affordable medicines to the Canadian market. Nora Pharma has 36 employees working at its 15,000-square-foot Health Canada-certified facility and offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma and its service arm, which commercializes under the name Lea Solutions, will continue to operate without changes. “Nora Pharma will operate as a subsidiary of Sunshine Biopharma, with Mr. Chamoun as president,” Slilaty said. “We are happy to have the Nora employees join the Sunshine Biopharma family.” About Sunshine Biopharma Sunshine Biopharma (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. In addition to working with the University of Arizona to develop a treatment for COVID-19, the company also develops Adva-27a, a unique anti-cancer compound. Sunshine Biopharma reports that tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying multidrug-resistant cancer cells, including pancreatic, small-cell lung, breast and uterine sarcoma cancer cells. Clinical trials for pancreatic cancer indication will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada, the company said. Sunshine Biopharma is also engaged in developing a novel anti-cancer mRNA called K1.1. The company says the data collected to date has shown that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug-resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3) and pancreatic cancer cells (SUIT-2). Studies using nontransformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery to patients using the proven mRNA vaccine technology. Learn more about the company here. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/

November 07, 2022 09:28 AM Eastern Standard Time

Video

Cold and Flu Season 2022: How Over-the-Counter Remedies Can Help

YourUpdateTV

Flu season has almost always been a predictable part of every winter, but the COVID-19 pandemic threw things out of whack. The 2020-2021 flu season was practically non-existent due to COVID-19 precautions and lockdowns, and last year’s flu season was definitely mild compared to pre-pandemic years. Recently, Best-Selling Author and Medical Contributor Dr. Ian Smith teamed up with Mucinex on a nationwide satellite media tour to discuss the upcoming cold and flu season and some resources that can help. A video accompanying this announcement is available at: https://youtu.be/c4AY6pLO1kU Many health experts are predicting the 2022-2023 flu season will be a severe one, due to several factors. The main reason the flu basically disappeared the last two years was the behavior changes people made to avoid COVID – staying home, avoiding public gatherings, wearing masks, and not traveling. That also prevented the flu virus from spreading like usual. Those measures have been mostly abandoned – in addition, without the last two ‘flu seasons’ many individuals’ immunity to seasonal flu will be decreased. It is possible that we could see a higher rate of severe illness due to the flu this year. Many experts have looked to Australia, where flu season runs from April to September. They are just coming out their most devastating flu season in five years, which could be a precursor as to what we can expect to see in the U.S. The best way to prevent and limit the effects if you do contact the flu is to get vaccinated. It can take up to two weeks for the vaccine to be most effective after administration, and since the influenza virus is already circulating, it is best to do this as soon as possible. Key preventative measures like washing your hands often and covering your nose and mouth with a tissue when you cough or sneeze and sneezing into your elbow if you don’t have a tissue can be extremely effective in preventing the spread of germs. If you do find yourself with flu-like symptoms, such as cough and congestion, there are options available to help you feel better and over-the-counter remedies are the first stop. While over-the-counter remedies don’t cure the flu virus, they can go a long way towards helping treat the symptoms. Dr. Ian’s go-to is Mucinex Extended-Release Tablets, because they are clinically proven to last up to 12 hours. As the #1 pharmacist recommended expectorant, Mucinex Extended-Release Tablets relieve chest congestion and thin and loosen mucus, which can provide relief for your chest congestion, making your cough more productive. People must use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. You can find Mucinex online at Mucinex.com or stop by Walmart or your local pharmacy retailer. About Dr Ian Smith Dr. Ian Smith is the author of the #1 New York Times bestselling books, SHRED: THE REVOLUTIONARY DIET, and SUPER SHRED: The Big Results Diet, and BLAST THE SUGAR OUT. Dr. Smith’s highly anticipated newest book, The Clean 20, became an instant New York Times best seller, helping hundreds of thousands of people reduce bad sugars from their diet, lose weight, lower blood sugar levels, and cut the cravings. Dr. Smith was appointed by President Obama to a second term on the prestigious President’s Council on Fitness, Sports, and Nutrition. He is currently the medical contributor and co-host of the nationally syndicated television show The Rachael Ray Show. He is a former co-host of the Emmy award winning syndicated daytime talk show, The Doctors. He also served as the medical/diet expert for six seasons on VH1’s highly-rated Celebrity Fit Club, and is the creator and founder of the national health initiatives The 50 Million Pound Challenge and The Makeover Mile. Dr. Smith is the former medical correspondent for NBC News network and for NewsChannel 4 in New York, where he filed reports for NBC Nightly News and The Today Show as well as WNBC’s various news broadcasts. He has appeared extensively on various broadcasts including The Oprah Winfrey Show, The View, Dr. Oz, Steve Harvey Show, The Talk, Larry King Live, Anderson Cooper 360, CNN, MSNBC and many more. He has written for various publications including Time, Newsweek, Men’s Fitness, and the New York Daily News, and has been featured in several other publications including, People, Redbook, Details Magazine, Essence, Ebony, University of Chicago Medicine on the Midway, Cosmopolitan, and Black Enterprise. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 04, 2022 10:05 AM Eastern Daylight Time

Video

Software Effective Solutions’ (OTC: SFWJ) Medcana Acquires Controlling Stake in Eko2o Environmental

Software Effective Solutions Corp.

McapMediaWire -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana has acquired a controlling stake in Eko2o Environmental Solutions S.A.S. of Medellin, Antioquia. a company focused on developing infrastructure for agriculture, primarily with greenhouse construction and irrigation systems in Colombia and South America. With this acquisition, the Company is expanding its infrastructure and overall capabilities toward additional market opportunities and strategic partnerships. Juan Ricardo Velez is CEO for Eko2o and is renown in the industry for his experience and track record for success. As well, execs are confident that the engineering talent and vendor support that comes with this acquisition will set Eko20 as a market leader in Colombia and South America very quickly. Gabriel Diáz, CEO of Medcana states “This acquisition further amplifies our investments in the industry and provides expansive opportunities for growth in the industry. We are honored to be working with a team equipped with a deep understanding of, and extensive experience in greenhouse and irrigation technologies. We are building something special here and Eko2o is a very important piece of our puzzle.” Juan Ricardo Velez CEO and founder of Eco2o is a Civil Engineer from University of Medellin, served and retired as army Major in Colombian Army. He has advanced studies in Israel and Spain focusing on irrigation systems and greenhouses. His experience and his team are unrivaled in Colombia and most of South America. About Software Effective Solutions/MedCana: Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. The recent acquisition of a software company expanded the offering to provide traceability from plant to product. MedCana's initial focus is on developing clients and companies in Latin America, with an initial focus on Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Signed. /s/ Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co FOR MORE INFORMATION PLEASE CONTACT: Chris Greta 512-587-5175 chris@chrisgreta.com www.medcana.net info@medcana.co Contact Details Chris Greta +1 512-587-5175 chris@chrisgreta.com Company Website https://www.medcana.net/

November 03, 2022 10:57 AM Eastern Daylight Time

News Release

Livewire’s Estrella Weedery Is The World’s First Estate-Grown Weedery — A Sustainable Cannabis Farm and Destination Focused On Premium Organic-Style Specialty Cannabis Products

LiveWire Ergogenics, Inc.

Livewire Ergogenics Inc. trading at the OTC Marketplace under (OTCMKTS: LVVV) is a company focused on acquiring, managing, leasing, and licensing special-purpose real estate properties and operations conducive to producing high-quality, handcrafted, and organically grown specialty cannabis products for medical and recreational adult-use in California. The company’s main operations are in Paso Robles, California, including the recently acquired Estrella Ranch nestled among hundreds of world-renowned vineyards and Makana Ola Farms In Humboldt, California. The company says the Estrella Ranch property is the home to the world’s first “Estate Grown Weedery”, following the well-established vineyard business model, eventually developing it into a cannabis tourist destination in California. Already an active cannabis-producing property, the company is turning Estrella Ranch into multiple revenue-stream properties while preserving its natural splendor and prioritizing environmentally conscious cultivation and business practices every step of the way, leaving behind the smallest possible carbon footprint possible. Handcrafted Organic Cannabis Specialty Products May Help Keep Profit Margins High With its initial pilot harvest completed last October, Livewire took the first step toward establishing the Estrella Weedery brand. The harvest was carried out by Livewire’s affiliate company, Estrella River Farms which operates the cultivation on the Estrella property. ERF is using state-of-the-art techniques to develop a sustainable, organic farm for growing a variety of premium cannabis specialty products. The tractorless cultivation process uses less water, less fertilizer, and no toxic pesticides. The result is high-potency, premium cannabis that takes considerably less water than comparable cultivation processes to produce. To stay competitive with bigger California producers like Lowell Farms Inc. (OTCQX: LOWLF) or Glass House Brands (OTCQX: GLASF), LiveWire’s Estrella River Farms is focused on cultivating organic-style specialty products with higher profit margins. By focusing on quality instead of quantity (grow by the pound - sell by the gram), the company hopes to avoid the high cost and low return of mass-produced cannabis. As the trend toward widespread legalization continues with 52% of Americans living in areas with marijuana legalized in some form, the cost of cannabis has dropped in the United States, sinking to its lowest price in over three years in June. In Canada, nationwide legalization was followed by a 13% drop in price in the first year. Since then, retail prices across categories have continued to dip as more producers entered the space still having to compete with larger illicit sales for market share. While that drop will likely level out, companies with tight margins are going to have a hard time staying competitive without differentiating their products in distinctive ways. For Livewire, that differentiation comes from quality specialty products, environmentally conscious production, and operating with significantly lower production costs to keep profit margins high. In addition to its business-to-business sales, the company intends to get its premium Estrella Weedery branded product onto every dispensary shelf in California — either as a specialty product under its own brand or as a licensed private-label product under third-party brands. Livewire has also partnered with home-delivery services Kushagram and Green Eagle to deliver its cannabis products directly to consumers. Applying The Tried And True Vineyard Model To Cannabis Cultivation Is Expected Generate Additional Revenue The ultimate vision at Estrella Ranch is simple: Sell its high-quality specialty products B to B and Direct to Consumers. Ultimately, create an idyllic wellness retreat complete with scenic vistas and currently over 130,000 square feet of sustainably cultivated cannabis, multiple offices, secure storage buildings, and large living quarters. When the project is finished, Livewire hopes to have roughly six (6) acres of outdoor growing area, and 22,000 square feet of indoor cultivation,— all while carefully preserving the natural, open landscape of rolling hills and well-watered ranchland. Livewire’s Plan Is to Generate Multiple Revenue Streams From One Low-Cost Operation Livewire chose the Estrella Ranch location, in part, for the ideal micro-climate that makes organic, sun-grown outdoor cannabis cultivation possible. In less ideal climates, cultivators typically opt for indoor production to increase yield and compensate for poor weather or lack of sun. But growing indoors means spending more on energy, facility maintenance, and other expenses that bring median average production costs up to $472 per pound. At Estrella, Livewire says production costs average under $100 per pound for its organic-style outdoor cultivation. The company states that the lower production cost paired with its plan to eventually generate revenue from the property via a first-of-its-kind cannabis wellness retreat and both direct-to-consumer and business-to-business sales of the cannabis it grows creates the potential for a wide margin and substantial growth potential. Livewire Ergogenics Inc. focuses on acquiring, managing, and licensing well-qualified cannabis real estate locations to establish fully compliant and permitted facilities to produce cannabis-based products and establish relationships for the statewide distribution of these products in California. This includes developing and licensing high-quality organic cannabinoid-based products and services and creating the high-quality "Estrella Grown Weedery™" brand via its subsidiary/affiliate companies Estrella Ranch Partners, Estrella River Farms, Makana Ola, and CaliCruz Farms. LiveWire Ergogenics does not produce, sell, or distribute products that violate the United States Controlled Substances Act. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Tristan Cavato ir@livewireergogenics.com

November 02, 2022 08:15 AM Eastern Daylight Time

PROTEXT MOBILITY, INC. (TXTM) AND RSAMMDA LLC (DELAWARE) PROVIDES SHAREHOLDER UPDATE

ProText Mobility, Inc.

Protext Mobility, Inc. (OTC PINK: TXTM) and RSAMMDA LLC (Delaware) (“RSAMMDA.LLC”) are pleased to provide the following shareholder update and announce an initial order for 2.33 million pounds of Genus Cannabis Sativa under a supply agreement. Dr. Ahmed Jamaloodeen (Dr.J), Protext Chairman commented, “This is a terrific milestone and demonstrates years of hard work and relentless pursuit of educating the masses and government collaboration. The initial order calls for the delivery of 2.33 million pounds of cannabis, arguably the largest single cannabis flower and biomass order in history to date post legalization. The specific strain we are growing for this order is Charlottes Angel for high percentage CBD flower and biomass. Everything we do is under South Africa federally issued permits, and license to import, export, grow hemp and cannabis from seed to sale, R & D, as well as develop and distribute our own brand of finished products. “Our proprietary, branded CBD product line and online marketplace is anticipated to launch shortly. Due to our early pioneering of hemp and cannabis as a massive community uplift opportunity in South Africa, we were approved as the first government sponsored pilot project that would enable proof of concept to other farms as a blueprint of this business model. This early blueprint is now a proven business model for South African farmers, and we are now at the forefront of SA becoming a recognized global leader in hemp and cannabis production. To further these efforts, last week I attended the AFASA AGM conference and gave a presentation to 1000’s of farmers who are now part of the Cannabis Commodity Cluster Formation, which I’ve been appointed as National Cannabis Commodity Chairman – The first in history.” (link to Dr.J Cannabis Expo 2022 presentation discussing SA community uplift and cannabis: youtube.com/DR.J ) Dylon Du Plooy, Protext CEO, commented, “The hemp renaissance is well underway, with renewed interest from global industrial companies to find cheaper and greener resources that can be used to produce 1000’s of end product. America is decades behind the sustainable materials revolution. That represents a big opportunity for us to unlock the potential of industrial hemp in the world’s strongest economy, with the lowest cost product available globally. For South Africa, the opportunity is to take a global role in what we believe is the beginning of an industrial hemp renaissance. We can not only produce product at the lowest cost basis on a global basis, but we can monetize the farm with 3 annual grows, making our hemp, biomass, and cannabis much sought after from customers around the world. In fact, this substantial off take agreement for an initial 2.3 m illion pounds is being delivered to a US customer. Why? Not only for the quality of the product, but our cost basis is so competitive we can deliver product that includes freight shipping cost to US customers, that is lower than they can get anywhere in North America.” #TXTMTribe #TXTMTribeRaok #TXTMRaok. Dr. J continued, “As we have previously discussed, we believe there is significant value in the human capital derived from our knowledge, Government and other relationships, compliance, resources, facilities, biomass, and infrastructure that is invaluable. The Permits we are in possession of allow for Genus Cannabis Sativa import, export, grow & cultivation, research, testing, and end product development for global distribution, all of which are anticipated to be utilized by Protext with the end goal to commercialize the live plant extraction technology and bring superior end products to the global market. Having technology that’s been tested and proven to increased bioavailability by 10-15x is significant and puts us miles ahead of all competitors. Additional testing is anticipated to be conducted with cannabis being grown on the farm right now. The testing will focus on maximizing yield as well as testing various strains of Genus Cannabis Sativa. We will also begin conducting the R&D using the New Age Extraction Technology for other Indigenous Plant Flora with medicinal properties including Psilocybin. We believe that the significance of the implications our live plant Extraction Technology can have on not only our yield, but also on an entire industry with its 10-15X Bioavailability has been over looked due to the complexity of the science. In layman’s terms we stand to produce Natural Plant Based Medicine with 10-15 times more bioavailability than current products on the market, at a fraction of the cost. “As we previously discussed, but worth repeating, we entered into this transaction with Protext as we believe there to be numerous synergies by allowing access to certain assets of our established business’ with Protext as well as commercialize the Protext proprietary live plant extraction technology and processes into our existing Genus Cannabis Sativa infrastructure. Prior to the merger, Protext had collaborated with RSAMMD whereby the companies utilized Protext’s proprietary live plant extraction technology along with Kettle extraction equipment to conduct a series of live cannabis extraction testing at New Castle Farm under permits for Genus Cannabis Sativa, with the goal to produce an emulsion rich with cannabinoid but with little to no conversion of THC-A to psychoactive THC. We undertook a series of tests to prove out that the Kettle system and extraction technologies did what they were supposed to do. As part of our previous investigations, various tests were completed using live cannabis flower and leaf, rendered into liquid emulsions supplied by the farm in New Castle. Prior to now, it was hypothecated that processing live Genus Cannabis Sativa under lower temperatures would yield a rich nano-emulsion of phytocannabinoids while retaining the non-psychoactive precursor acid form (THC-A). Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for advancement of medical research using non-psychoactive cannabis. What has also intrigued us are the findings from prior research and clinical trials that have shown that the Kettle system, when applied to other medicinal plants, can create an extract that is significantly more bioavailable (10-15x) than a standard extract. This means that our cannabis extract should be more potent while providing a dose that could potentially last up to 24 hours in the bloodstream, which is in-line with prior clinical results using other medicinal plants. Medically, this opens the door to a line of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior outcomes. From a business perspective, an increase of bioavailability in that magnitude can be a game changer for cultivators as it essentially could increase the net yield by a factor of 10-15x per plant, per acre, per farm. This initial order is just the beginning and leadership is excited for what’s to come. We will lead the change we want to see in our world” concluded Dr.J. CONTACT INFORMATION For further information, or inquiries relating to partnerships in SA, JV opportunities and/or off-take/supply agreements please feel free to contact us Dylon Du Plooy at: dylon@rsammd.co.za Dr.J at: exportintl@aol.com Follow us at: https://twitter.com/RSAMMD https://twitter.com/ProtextP About Protext (OTC PINK: TXTM) Through its prior acquisitions, Protext has engaged in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology. Website: www.protxtm.com About RSAMMDA.LLC: RSAMMDA.LLC. is a wholly owned subsidiary of TXTM focused on acquisitions with two principals, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”). Mr. Du Plooy is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Dr. J operates the 5000 Hectare New Castle Farm as well as federally issued hemp permits issued by the Government of South Africa. Together, we partner with leading hospitals and universities globally to advance the clinical benefits and applications of cannabinoids. RSAMMDA.LLC founders are a group of medical doctors and pharmacists, and cannabis activists who have been at the forefront of medical cannabis legislation and South African cannabis legalization, which took place in September 2018. We are committed to the advancement of technology and scientific research that leads to an improved quality of life for patients around the world. Website: www.rsammda.com Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward- looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward- looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation. Contact Details Dylon Du Plooy +27 72 889 2581 dylon@rsammd.co.za Company Website https://www.protxtm.com/

November 01, 2022 02:57 PM Eastern Daylight Time

FORGOTTEN MOM LAUNCHES CAPITAL CAMPAIGN FOCUSING ON MOTHERS WITH ADDICTION, A DRAMATICALLY UNDERSERVED POPULATION

Forgotten Mom Inc.

In an effort to improve outcomes and better support mothers struggling with addiction, a capital campaign for Forgotten Moms is launching today in Florida. According to data collected by the National Institute of Health (NIH), 22M Americans struggle with addiction, 23M are in addiction recovery, and 45M are directly impacted by addiction. Of those checking into treatment centers, 32% are mothers. Additionally, these women need inpatient and outpatient treatment, as well as housing to keep families together and mothers supported. Historically, many women are pushed through the court system on drug charges, where they may end up in jail, separated from their children, with many children going into foster care. Dr. Anita Cocoves, from the Critical Incident Stress Management Team of the Treasure Coast in Florida says, “As we continue to see issues with the opioid epidemic and treatment, women continue to be homeless, without care, and emotionally hopeless. They desperately need treatment, education, and longer-term support to stay healthy.” Farid Dallal, Advisor to NueroPsychiatric Addiction Treatment of Port St. Lucie, Florida, has been underwriting treatment for the last five years with his own money and has spent close to $200,000 providing scholarships for treatment service and access to over 500 people. In 2016, he created the charity, non-profit Forgotten Mom, and is now raising funds to build out a new treatment and housing facility, along with longer-term resource and education supports. Dallal says, “In the past two years, we have lost three non-profits in the South Florida area who have served these women. There is nothing for them. They need a place that is safe, trustworthy, and somewhere to keep their families together. We will be providing longer term educational support as well, to prevent relapse.” The Forgotten Mom Capital Campaign seeks to raise $2.68M and will run through 2023 with a fundraiser and documentary film in development now. They continue to build awareness and services regionally, nationally, and internationally for this necessary treatment. Adriana Cottet, lead coordinator of the capital campaign, adds, “We invite everyone to donate to this critically underserved population. Our goal is to expand our services through this capital campaign and continue to serve more women and their families.” For more information, see www.forgottenmoms.org or info@forgottenmoms.org About Forgotten Mom: Forgotten Mom Inc. (FMI), is a registered (501(c)(3), non-profit initiative established in 2016 to address, support, and find help for the dramatically underserved population of mothers struggling with the disease of addiction. www.forgottenmoms.org Contact Details Farid Dallal +1 646-640-6099 info@forgottenmoms.org Company Website http://www.forgottenmoms.org

November 01, 2022 11:11 AM Eastern Daylight Time

Former Fortune 500 Healthcare Executive Joins AliMed, Inc., As Senior Vice President Of Commercial Growth And Development

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, announced today that Jeff Hastings has joined its Senior Leadership Team as the Senior Vice President of Commercial Growth and Development. In his new role, Hastings will lead AliMed’s national sales and sales support teams, spearheading commercial expansion of its product portfolio to strengthen the company’s position and market share in both the acute and post-acute care space. Additionally, Hastings will drive efforts to develop and execute programs with preferred suppliers, build on core contract positions within the GPO, federal government, and healthcare-provider segments, and enhance the customer experience. “Jeff has relentlessly proven over his more than 20 years in healthcare leadership to be a key cog in some very critical and highly strategic endeavors,” said Adam S. Epstein, CEO of AliMed. “He is superbly skilled at developing and leading high-performing sales teams with a track record for elevating companies to the next level. We are very excited to welcome Jeff and his talents to our team.” As an influential senior executive in the healthcare industry, Hastings brings decades of leadership experience to AliMed. He has led major corporate initiatives focused on strategic transformation, portfolio diversification, and revenue acceleration for long-term sustainability at some of the nation’s largest healthcare organizations, including Owens and Minor, Cardinal Health, Hill-Rom, Roche Diagnostics, and Vizient (formerly MedAssets). Most recently, Hastings was operating partner at Mountain Pacific Fund, a life sciences investment firm based in Salt Lake City. “AliMed has such a rich, mature, and robust foundation to build on,” Hastings said of AliMed’s more than 50 years in the medical products space. “There is a great sense of enormity in this opportunity, and I’m thrilled—with the support of Adam and a very dedicated AliMed team—to help bring this organization to new heights.” A native of Ohio, Hastings holds a master’s degree in Education from the University of Akron and a bachelor’s degree in Sports Medicine and Health Education from Ashland University. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Amy Fontaine Marketing Communications +1 857-205-8264 afontaine@alimed.com Company Website https://www.alimed.com/

November 01, 2022 10:00 AM Eastern Daylight Time

Image

Black Women, Breast Cancer and the Tests That Can Save Lives

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/13nWSPuDIAs The death rate from breast cancer continues to decline, according to a new report from the American Cancer Society. But there's a wide, worrisome gap in Black women's outcomes that remains unchanged. Black women are more likely to die from breast cancer than white women. While breast cancer incidence rates among Black and white women are close, mortality rates are markedly different, with Black women having a 41% higher death rate from breast cancer. Black women are disproportionally affected by more aggressive breast cancers because of their biology. A recent study showed that Black women are significantly more likely to have genomically High Risk tumors compared to white women, despite having the same clinical factors. This means that, all other things the same – right down to their age and the size of their tumors – the Black women in the study were more likely to have a more aggressive type of cancer. The way we can address some of these disparities is through genomic tests like MammaPrint and BluePrint, which look at 150 important genes within a tumor to estimate the risk of recurrence of that cancer. The number of genes/RNA analyzed by MammaPrint and BluePrint is higher than any other test, and captures the diversity of pathways that allows for consistent results regardless of race and ethnicity. With that information, we as physicians can make more informed decisions with our patients about what their optimal treatment plan should be. There are a few available genomic tests utilized in the clinic to guide discussions around chemotherapy benefit. One example is MammaPrint/BluePrint which are the most comprehensive tests with the most consistent results across diverse groups of patients, compared to other tests. In addition, only the BluePrint test can catch tumor subtypes that may look less dangerous, but actually behave more like triple negative breast cancer when you further classify. This is a very aggressive kind of cancer, that is over-represented among Black women. It is very important the gene expression profiling result a woman receives about her tumor is consistent and reliable regardless of her ethnicity and race, like MammaPrint and BluePrint’s. Studies showing mis-categorization of risk in minority populations due to under-representation of these patients in genomic studies and clinical trials that lead to the approval of these tests is alarming. Every woman with breast cancer has the right to know the correct and clear biological information from her tumor, regardless of her skin color, so she can make timely decisions about her treatment with her care team. For more information about gene expression profiling, including resources that can help you talk to your doctor to make sure the test being offered will work best and most accurately for you, go to Agendia.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2022 10:00 AM Eastern Daylight Time

Video

The Chicago School of Professional Psychology Produces 'Change Makers'

The Chicago School of Professional Psychology

The next generation of mental health professionals - some 275 “change makers” were awarded master’s and doctoral degrees last Friday at two commencement ceremonies for the Washington, DC campus of The Chicago School of Professional Psychology. The graduates enter a profession dealing with severe shortages at a time when experts say as many as one-in-five people in this country suffer from a mental disorder, and only half of those who need help can get it. In addressing the graduates, Dr. Michele Nealon, Psy.D. President of The Chicago School, said “I hope that your time as a Chicago School student has lit a fire within you – a fire to provide empathetic support for those in need. I urge you to follow your passion for service as far as you can and to light the way for others.” Joining Dr. Nealon in awarding diplomas was Dr. Donald Schultz, Ph.D, Chief Academic Officer of The Chicago School and Dr. Thelma Day, Ph.D., recipient of an honorary degree for her contributions as a counselor-educator, organizational leader and college professor. One of two student speakers was Dr. Akshaya Parthasarathi, Ph.D., a data analyst at the federal Office of Minorities and Women Inclusion, tasked by the U.S. Congress to develop policies to ensure equitable treatment of all by the nation’s financial institutions. She shared her story as an international student who is grateful to her professors and fellow students. “What looked like a distant dream for a girl from India, to study abroad in an institution like this, was made possible because of each of you. Accepting me as I am--allowing me to be different--has let me grow into a global citizen with varied experiences and stories in my pocket,” she said. “My goal is to share these experiences with people of the world, to show the power of community, and the success one can achieve when people let you be you.” Another student speaker, Dr. Bethany Patterson, Ph.D., serves as clinical director at Helianthus Positive Behavior Supports, provider of counseling services to children and families in Virginia and North Carolina. She told her story, as she sought an institution that would support her role as a military spouse and mother of three. “I needed a school that was supportive and respectful of the military lifestyle because I had unique needs,” she said. “I found a place where the learning environment is optimized by active learners with diverse cultures,” she said. “Today I embody The Chicago School’s values of innovation, service, and community-- I am giving back by creating a space to encourage other military spouses to further their education.” The Chicago School serves a majority minority student body in which two of three students identify as individuals of color. The 43-year old non-profit institution has more than 6,000 students enrolled in 30 degree and certificate programs. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 01, 2022 06:00 AM Pacific Daylight Time